Anaphylaxis

Post-survey responses show educators were eager to learn more about how to prevent students from experiencing food-anaphylactic reactions.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

In the initial report, investigators find just 2.5 cases of anaphylaxis per million doses of the Moderna COVID-19 vaccine.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

Investigators found that peanut allergy immunotherapy was associated with a greater risk of anaphylaxis, epinephrine use, and serious adverse events compared to avoidance or placebo.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Have current guidelines been fitted to consider the future of immunotherapy research?

UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.

Why it may be critical to reassess dosing practices being practiced in investigative food allergy therapies.

About 9 of 10 patients were able to safely consume foods containing peanuts in an eight-year, longitudinal observational study.

Kim and Commins discuss what the next series of data on the investigative peanut immunotherapies may mean for the field.

The therapy was further assessed in asthmatic patients with comorbid chronic rhinosinusitis and with or without nasal polyposis.

UNC School of Medicine colleagues Edwin Kim, MD, MS, and Scott Commins, MD, PhD, explain how the discussion around food allergy care has progressed this year.

How do current peanut allergy immunotherapies compare, and what other allergens may be addressed next?

Investigative therapy PVX108 showed a favorable tolerability and safety profile in patients with peanut allergies.

Why both physicians and patients need to be on the same page when considering food allergy oral immunotherapy.

Why peanut allergy therapies are prioritized in early trials, and how far out are complimentary therapies to the ones currently being investigated.

A group of pediatric patients were able to sustain desensitization 4 weeks after stopping the daily oral immunotherapy.

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?